OncoCyte develops non-invasive diagnostic tests using blood or urine samples to detect lung, bladder, and breast cancers. The company also aims to replace screening imaging procedures that do not meet the needs of patients, healthcare providers, or payers. OncoCyte operates in the United States and earns revenue from the sale of diagnostic tests.